Skip to Content

Elitek (rasburicase) Disease Interactions

There is 1 disease interaction with Elitek (rasburicase):

Major

Pegloticase/Rasburicase (Includes Elitek) ↔ G6Pd Deficiency

Severe Potential Hazard, High plausibility

Applies to: G-6-PD Deficiency

The antihyperuricemic agents pegloticase and rasburicase are contraindicated in patients deficient in glucose-6-phosphate-dehydrogenase (G6PD), as these have shown to cause severe hemolytic reactions and methemoglobinemia. Patients at high risk of G6PD deficiency such as patients of African, Mediterranean or Southern Asian ancestry, should be screened prior to starting treatment. Treatment with any of these drugs should be discontinued immediately and permanently in any patient developing hemolysis or methemoglobinemia.

Elitek (rasburicase) drug Interactions

There are 7 drug interactions with Elitek (rasburicase)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide